EcoDrugPlus

Phosphodiesterase 4b

Ensembl ID : ENSACIG00000013513
Gene Symbol: PDE4B
1 Cross references
226 Possible Orthologues:

Phosphodiesterase 4d

Ensembl ID : ENSACIG00000002655
Gene Symbol: PDE4D
1 Cross references
222 Possible Orthologues:

Phosphodiesterase 5a, Cgmp-Specific, B

Ensembl ID : ENSACIG00000012649
Gene Symbol: PDE5AB
2 Cross references
208 Possible Orthologues:

Phosphodiesterase 7a

Ensembl ID : ENSACIG00000022347
Gene Symbol: PDE7A
1 Cross references
215 Possible Orthologues:

Phosphodiesterase 7b

Ensembl ID : ENSACIG00000017160
Gene Symbol: PDE7B
2 Cross references
174 Possible Orthologues:

Phosphodiesterase 9a

Ensembl ID : ENSACIG00000003713
Gene Symbol: PDE9A
1 Cross references
192 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 2

Ensembl ID : ENSACIG00000010325
Gene Symbol: PIK3R2
1 Cross references
191 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSACIG00000019221
Gene Symbol: PIK3R3
1 Cross references
199 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 3

Ensembl ID : ENSACIG00000011810
Gene Symbol: PIK3R3
1 Cross references
188 Possible Orthologues:

Phosphoinositide-3-Kinase Regulatory Subunit 5

Ensembl ID : ENSACIG00000008265
Gene Symbol: PIK3R5
1 Cross references
202 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSACIG00000005149
Gene Symbol: PIK3R1
1 Cross references
197 Possible Orthologues:

Phosphoinositide-3-Kinase, Regulatory Subunit 1 (Alpha)

Ensembl ID : ENSACIG00000014989
Gene Symbol: PIK3R1
1 Cross references
203 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).